• Product name

    Anti-PARK7/DJ1 antibody [malphaDJ-1/E2.19]
    See all PARK7/DJ1 primary antibodies
  • Description

    Mouse monoclonal [malphaDJ-1/E2.19] to PARK7/DJ1
  • Host species

  • Specificity

    This clone has been shown to specifically recognise a fusion protein of PARK7/DJ1. It also recognises a FLAG-tagged PARK7/DJ1 expressed in eukaryotic cells. A single band is seen when Western blotting in optimised conditions with this clone. However, overloading the gel or using low dilutions can cause other bands to appear.
  • Tested applications

    Suitable for: Flow Cyt, IHC-Fr, ICC/IF, WB, ICC, IHC-FoFrmore details
  • Species reactivity

    Reacts with: Human, Zebrafish
    Does not react with: Mouse
  • Immunogen

    Recombinant full length protein corresponding to Human PARK7/DJ1.

  • Positive control

    • WB: HeLa whole cell lysate. Flow Cytometry: HepG2 cells.
  • General notes

    This antibody clone is manufactured by Abcam.

    This monoclonal antibody to DJ-1 has been knockout validated in Western blot. The expected band for DJ-1 was observed in wild type cells and the band was not seen in knockout cells.

    If you require this antibody in a particular buffer formulation or a particular conjugate for your experiments, please contact orders@abcam.com or you can find further information here.



Our Abpromise guarantee covers the use of ab11251 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt 1/100.

ab91545 - Mouse monoclonal IgM, is suitable for use as an isotype control with this antibody.

IHC-Fr Use at an assay dependent concentration.
ICC/IF 1/500.
WB Use at an assay dependent concentration. Detects a band of approximately 20 kDa.
ICC Use at an assay dependent concentration.
IHC-FoFr 1/1000.


  • Function

    Protects cells against oxidative stress and cell death. Plays a role in regulating expression or stability of the mitochondrial uncoupling proteins SLC25A14 and SLC25A27 in dopaminergic neurons of the substantia nigra pars compacta and attenuates the oxidative stress induced by calcium entry into the neurons via L-type channels during pacemaking. Eliminates hydrogen peroxide and protects cells against hydrogen peroxide-induced cell death. May act as an atypical peroxiredoxin-like peroxidase that scavenges hydrogen peroxide. Following removal of a C-terminal peptide, displays protease activity and enhanced cytoprotective action against oxidative stress-induced apoptosis. Stabilizes NFE2L2 by preventing its association with KEAP1 and its subsequent ubiquitination. Binds to OTUD7B and inhibits its deubiquitinating activity. Enhances RELA nuclear translocation. Binds to a number of mRNAs containing multiple copies of GG or CC motifs and partially inhibits their translation but dissociates following oxidative stress. Required for correct mitochondrial morphology and function and for autophagy of dysfunctional mitochondria. Regulates astrocyte inflammatory responses. Acts as a positive regulator of androgen receptor-dependent transcription. Prevents aggregation of SNCA. Plays a role in fertilization. Has no proteolytic activity. Has cell-growth promoting activity and transforming activity. May function as a redox-sensitive chaperone.
  • Tissue specificity

    Highly expressed in pancreas, kidney, skeletal muscle, liver, testis and heart. Detected at slightly lower levels in placenta and brain. Detected in astrocytes, Sertoli cells, spermatogonia, spermatids and spermatozoa.
  • Involvement in disease

    Defects in PARK7 are the cause of Parkinson disease type 7 (PARK7) [MIM:606324]. A neurodegenerative disorder characterized by resting tremor, postural tremor, bradykinesia, muscular rigidity, anxiety and psychotic episodes. PARK7 has onset before 40 years, slow progression and initial good response to levodopa. Some patients may show traits reminiscent of amyotrophic lateral sclerosis-parkinsonism/dementia complex (Guam disease).
  • Sequence similarities

    Belongs to the peptidase C56 family.
  • Post-translational

    Sumoylated on Lys-130 by PIAS2 or PIAS4; which is enhanced after ultraviolet irradiation and essential for cell-growth promoting activity and transforming activity.
    Cys-106 is easily oxidized to sulfinic acid.
    Undergoes cleavage of a C-terminal peptide and subsequent activation of protease activity in response to oxidative stress.
  • Cellular localization

    Cytoplasm. Nucleus. Mitochondrion. Under normal conditions, located predominantly in the cytoplasm and, to a lesser extent, in the nucleus and mitochondrion. Translocates to the mitochondrion and subsequently to the nucleus in response to oxidative stress and exerts an increased cytoprotective effect against oxidative damage. Detected in tau inclusions in brains from neurodegenerative disease patients.
  • Information by UniProt
  • Database links

  • Alternative names

    • CAP1 antibody
    • DJ-1 antibody
    • DJ1 antibody
    • DJ1 protein antibody
    • Epididymis secretory sperm binding protein Li 67p antibody
    • FLJ27376 antibody
    • FLJ34360 antibody
    • FLJ92274 antibody
    • HEL S 67p antibody
    • Oncogene DJ1 antibody
    • OTTHUMP00000001348 antibody
    • OTTHUMP00000001349 antibody
    • OTTHUMP00000001350 antibody
    • OTTHUMP00000001351 antibody
    • PARK7 antibody
    • PARK7_HUMAN antibody
    • Parkinson disease (autosomal recessive, early onset) 7 antibody
    • Parkinson disease protein 7 antibody
    • Parkinson protein 7 antibody
    • Protein DJ-1 antibody
    • SP22 antibody
    see all


  • Western blot using ab11251 at 1/500 on HeLa whole cell lysate (20µg/lane).

    Western blot using ab11251 at 1/500 on HeLa whole cell lysate (20µg/lane).
  • Western blot using clone malphaDJ-1/E2.19 and a beta actin antibody as a loading control.

    The bottom band is PARK7/DJ1, the top band is beta actin.

    Lane 1: 293 cell lysate
    Lane 2: MCF-7 cell lysate
    Lanes 3-7: various different prostate cell lines
    Lane 8: recombinant PARK7/DJ1 (that was used as immunogen for this antibody)

  • Lane 1: Wild-type HAP1 cell lysate (20 µg)
    Lane 2: PARK7/DJ1 knockout HAP1 cell lysate (20 µg)
    Lane 3: HeLa cell lysate (20 µg)
    Lane 4: Human brain tissue lysate (20 µg)
    Lanes 1 - 4: Merged signal (red and green). Green - ab11251  observed at 24 kDa. Red - loading control, ab181602, observed at 37 kDa.

    ab11251 was shown to specifically react with PARK7/DJ1 in wild-type HAP1 cells. No band was observed when knockout samples were used. Wild-type and PARK7/DJ1 knockout samples were subjected to SDS-PAGE. ab11251 and ab181602 (loading control to GAPDH) were diluted at 1/500 and 1/10,000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (ab216772) and Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (ab216777) secondary antibodies at 1/10,000 dilution for 1hr at room temperature before imaging.

  • ICC/IF image of ab11251 stained human HeLa cells. The cells were PFA fixed (10 min), permabilised in TBS-T (20 min) and incubated with the antibody (ab11251, 1:500 dilution) for 1h at room temperature. 1%BSA / 10% normal goat serum / 0.3M glycine was used to quench autofluorescence and block non-specific protein-protein interactions. The secondary antibody (green) was Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red). DAPI was used to stain the cell nuclei (blue).
  • Overlay histogram showing HepG2 cells stained with ab11251 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab11251, 1/100 dilution) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgM [ICIGM] (ab91545, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in HepG2 cells fixed with 4% paraformaldehyde (10 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.


This product has been referenced in:

  • Lin Y  et al. High expression of DJ-1 promotes growth and invasion via the PTEN-AKT pathway and predicts a poor prognosis in colorectal cancer. Cancer Med 7:809-819 (2018). WB, IHC-P . Read more (PubMed: 29441725) »
  • Qin LX  et al. BAG5 Interacts with DJ-1 and Inhibits the Neuroprotective Effects of DJ-1 to Combat Mitochondrial Oxidative Damage. Oxid Med Cell Longev 2017:5094934 (2017). Read more (PubMed: 28348719) »
See all 9 Publications for this product

Customer reviews and Q&As

1-7 of 7 Abreviews or Q&A

Western blot
Human Cell lysate - whole cell (cancer cell lines)
Gel Running Conditions
Reduced Denaturing (12)
Loading amount
30 µg
cancer cell lines
Blocking step
BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 3% · Temperature: 25°C

Abcam user community

Verified customer

Submitted Jun 05 2019


Thank you for your enquiry.

I have investigated our records for ab11251. I am sorry toconfirm there is an error on the datsheet and that this antibody is sold as ascites. The datasheet has been updated with the correct information and I apologize for any confusion.

The quality of our antibodies and datasheets is very important to us, as is any feedback and data we receive. It is regrettable that the information we had on this particular antibody was not of the standard both we and our customers expect from our products.

With regards to the concentration, unpurified antibodies, such as those sold as whole antiserum, ascites or tissue culture supernatant will not have a concentration stated on the datasheet. Antibody concentration is usually determined by protein assay, and ascites will contain a lot of other proteins, which means the antibody quantification would not be accurate.

I can confirm that for ascites, concentration of antibody is known to vary between 5 - 10 mg/ml.

I am sorry we are not able to provide an exact concentration on this occasion, but hope this information will be helpful to you.

If you have any further questions, please do not hesitate to contact me.

Read More


Thank you for contacting us and reporting the problems you have encountered with ab11251. Unfortunately xxx is away today but she has asked me to get in contact with you.

xxxxhas been investigating how the antibody is produced and purified in house and why there may be a difference in the two vials that you have received and shewill get back to you with this informationas soon as she hasit. In the meantime, if you wouldn'tmind, could you provide a few moredetails of whatproblems you havebeen experiencing with this antibody?I have attached aquestionnaire to this email for this purpose. Thiswill help greatly in investigating this case further and initiating any additional in house testing where necessary. Ifyou could provide images of theantibodyworking andof the latest results that wouldbevery useful.

As discussed with Kate, although this antibody has not been tested by us for paraffin embedded IHC and would therefore not normally be covered by the Abrpomise, as youhave previously found it to besuccessful in this application we can extend the Abpromise guarantee as a good-will gesture. I am thereforeable to offer you areplacement of thisantibody with adifferent lot,a different antibody altogether (such as https://www.abcam.com/PARK7-DJ1-antibody-ab18257.htmlwhich has been used in paraffin embedded IHC) or if you would prefer, a refund.

I apologise for the inconvenience this problem has caused and look forward to hearinghow you wouldlike to proceed.

Read More
Western blot
Human Cell lysate - whole cell (normal fibroblasts)
Loading amount
40 µg
normal fibroblasts
Gel Running Conditions
Reduced Denaturing (12 % polyacrylamide gel)
Blocking step
BSA as blocking agent for 12 hour(s) and 0 minute(s) · Concentration: 1% · Temperature: 22°C

Dr. Paule Benit

Verified customer

Submitted May 03 2010

Immunocytochemistry/ Immunofluorescence
Human Cell (normal human fibroblasts)
normal human fibroblasts
Yes - 1X PBS 0.25% Triton
Blocking step
BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 1% · Temperature: 37°C

Dr. Paule Benit

Verified customer

Submitted Apr 23 2010


Thank you for your enquiry. Ab11251 has been tested for application in Western blotting and Immunocytochemistry, and has not yet been tested in any other applications (including IP). For Western blotting, I would recommend starting at a dilution of 1:500, and for ICC I would recommend starting at a dilution of 1:100. Please optimize based upon your results. If you decide to go ahead and purchase this product, please let us know how you get on by submitting an Abreview and in return we will award you 50 Abcam Points, which can be redeemed on a number of rewards (a further 100 Abcam Points will be offered for an image). If you have any additional questions, please contact us again.

Read More


Thank you very much for your enquiry and for your patience. Ab11251 was originated outside Abcam and according to the originator, they had positive feedback from a researcher who found the antibody to cross-react with zebrafish. That is unfortunately all the information that I have regarding the antibody's cross-reactivity with zebrafish. I saw that you are using ab11251 with PFA fixed brain tissue. To our knowledge, this antibody has only been tested for application in Western blotting and Immunocytochemistry. We don't have any information about how ab11251 works in IHC. At this point I would like to make the following suggestions. The PFA fixative may be modifying the epitope that the antibody recognizes and so I would suggest doing an antigen retrieval step in order to unmask the epitope. Also, you didn't mention which dilutions of ab11251 that you have tried but you may want to increase the concentration. If you have any additional questions, please contact us again.

Read More

For licensing inquiries, please contact partnerships@abcam.com

Sign up